GENE THERAPY FOR INHERITED RETINAL DISEASES
Rewriting the genetic code of Inherited Retinal Diseases : A CERA PARTNERSHIP
Usher Syndrome
and
Retinitis pigmentosa
The Leading Cause of Inherited Retinal Diseases (IRDs) such as Usher Syndrome and Retinitis Pigmentosa is a devastating genetic condition affecting over 4M people worldwide.
Large-gene indications like USH2A and EYS exceed standard viral vector capacities. Our technology developed under Adara Bio, edits RNA rather than replacing whole genes, while being completely independent of gene size.
Type 2A, the most prevalent form, accounts for nearly 60% of all cases.
Currently, there is no cure and no treatment—leaving patients to face an inevitable transition into a world of silence and darkness.
FOR USHER SYNDROME ;
Why Gene Therapy is the Only Answer
Traditional medicine can manage symptoms, but it cannot stop genetic decay in IRDs.
To save sight, we must go to the source.
By correcting the genetic code at the RNA level rather than permanently altering DNA, we offer a safer, reversible, and highly precise solution- through Adara's RNA editing platform EDITRA™ .
This isn't just disease management— it is a quest to restore a lifetime of vision
25+ Years of World-Class Research Excellence To solve one of the most complex challenges in medicine, we partnered with the Centre for Eye Research Australia (CERA) to form Adara Bio - a joint venture between CERA and MVA.
Ranked among the world’s elite ophthalmology research institutions, CERA brings:
Scientific Authority
Two decades of translating laboratory breakthroughs into life-changing clinical trials.
Cutting-Edge Tech
Access to patient-derived retinal organoids ("mini-retinas") and advanced Cas13bt3 RNA editing platform- EDITRA™ .
Proven Track Record
An unparalleled infrastructure of cellular biology labs and clinical trial networks.
in partnership with
The CERA partnership
Our partnership is developing a potentially curative RNA Base Editing therapy designed to address the genetic diversity of Inherited Retinal Diseases.
Image taken by Anna Carlile, courtesy of CERA.
A 50:50 Vision for the Future
Our Joint Venture represents the pinnacle of Australian innovation. It is a perfect fusion of Clinical Authority and Commercial Mastery:
CERA provides the world-class research infrastructure and the revolutionary IP behind the RNA editing platform.
MedicVision AI provides the strategic commercial pathway, capital management, and the massive distribution network across the Asia-Pacific.
The platform is designed to enable the development of a scalable pipeline of precision therapies for retinal diseases with significant unmet medical need, by precisely correcting disease-causing mutations at the RNA level. EDITRA™ provides a flexible and adaptable approach that can be programmed for different genetic targets while avoiding permanent changes to DNA.
Strategic
Milestone
Current Status
Proof-of-Concept Validation confirmed in patient-derived models.
Goal
Advancing toward IND-enabling studies to bring the first human trials to the Asia-Pacific.